> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Vumerity
- URL: https://www.fdaweb.com/regulatory-review-period-for-vumerity/
- Published: 2022-07-26T12:00:00.000Z
- Updated: 2026-09-14T17:53:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152364

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Alkermes’ Vumerity (diroximel fumarate), indicated for treating certain relapsing forms of multiple sclerosis. The review period is 1,944 days, of which 1,623 days occurred during the testing phase and 321 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-07-25/pdf/2022-15823.pdf?ref=fdaweb.com).